Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00364715 |
Recruitment Status :
Completed
First Posted : August 16, 2006
Last Update Posted : August 17, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Recent studies have shown that dysregulation of ANXA1 expression are associated with tumorigenesis. Overexpression of ANXA1 protein is found in a wide variety of human tumors, such as breast 10, liver 11, pancreatic cancer14 and glial tumors15. In contrast, reduced levels of ANXA1 protein expression have been reported in ESCC4, 5, gastric6, breast7, head and neck SCC8 and prostate cancer9. No previous study on ANXA1 protein expression has been reported in the cancer of oral cavity. Furthermore, although alterations in annexin expression in different types of tumors have been described, no correlation has been established between ANXA1 and overall patient survival yet.
ANXA1 is a major cellular substrate of the oncogenic tyrosine kinases such as EGF receptor and hepatocyte growth factor (HGF) receptor, c-met. Previously, we have shown that expression of HGF and c-met is significantly associated with the progression of OSCC in Taiwan. Kermorgant et al. recently showed that PKC controls HGF-dependent c-met traffic, signaling and cell migration. Prior study indicate that the mitogen phorbol-12-myristate 13-acetate (PMA) induced ANXA1 nuclear translocation in a PKCdelta-dependent manner and ANXA1 nuclear translocation may participate in the regulation of cellular proliferation and the differentiation. However, it is not known whether HGF can induce ANXA1 nuclear translocation or not and how this relates to the pathogenesis of oral SCC.
In this study we aimed to investigate whether HGF induced the translocation of ANXA1 protein to the nucleus in OSCC cells and the role(s) of ANXA1 nuclear localization in the carcinogenesis of OSCC using an immunohistochemical technique. The data suggest a novel mechanism for HGF-induced ANXA1 protein nuclear translocation that may play an important role in the pathogenesis and prognosis in oral SCCs.
Condition or disease |
---|
Squamous Cell Carcinoma |

Study Type : | Observational |
Observational Model: | Case-Control |
Time Perspective: | Other |
Official Title: | Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer |
Study Start Date : | January 2005 |
Study Completion Date : | December 2005 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 26 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
noraml, dysplasia, SCC
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364715
Taiwan | |
National Taiwan University Hospital | |
Taipei, Taiwan, 100 |
Principal Investigator: | Mark YP Kuo, PHD | National Taiwan University , Dental Department |
ClinicalTrials.gov Identifier: | NCT00364715 |
Other Study ID Numbers: |
9561702012 |
First Posted: | August 16, 2006 Key Record Dates |
Last Update Posted: | August 17, 2006 |
Last Verified: | August 2006 |
Nuclear localization, annexin A1, oral SCC |
Mouth Neoplasms Neoplasms Head and Neck Neoplasms |
Neoplasms by Site Mouth Diseases Stomatognathic Diseases |